Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for mild to moderately severe COVID-19
jRCT2071200078Phase 2Completed
- Start
- Jan 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Colchicine with Placebo (2 arms). Primary endpoint: Area under the curve of change in serum C-reactive protein. Started Jan 2021; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071200078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200078.